You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》瑞信下調和鉑醫藥-B(02142.HK)目標價至12元 評級「跑贏大市」
阿思達克 09-03 09:48
瑞信發表研究報告指,和鉑醫藥(02142.HK)上半年收入220萬美元,較去年同期的610萬美元大幅下跌,主要由於今年無錄得分子許可費貢獻。期內研發開支按年增加171%,來自於額外的臨床試驗、早期研發項目數量增加,以及增聘研究人員所致。 瑞信認為,核心產品Batoclimab繼續為公司未來發展重點之一,目前已獲准在今年下半年開展用於治療全身性重症肌無力(gMG)的第三期臨床研究,計劃明年向國家藥品監督管理局提交生物製品許可申請,另有計劃提交兩項生物製品補充許可證申請。 現有的8款臨床前研究項目,公司預期今年及明年分別會提交2款及4款新藥上市申請。瑞信表示,由於研發及行政費用增加,將2021至2023年每股虧損預測調整至0.08、0.08及0.11美元,目標價由14元降至12元,但基於強勁產品線,維持「跑贏大市」評級。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account